CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial

Lancet

Volumn 368, Issue 9534, 2006, Pages 459-465

  Ananworanich, Jintanat ^a   Gayet Ageron, Angèle ^b   Le Braz, Michelle ^b   Prasithsirikul, Wisit ^c   Chetchotisakd, Ploenchan ^d   Kiertiburanakul, Sasisopin ^e   Munsakul, Warangkana ^f   Raksakulkarn, Phitsanu ^g   Tansuphasawasdikul, Somboon ^h   Sirivichayakul, Sunee ^l   Cavassini, Matthias ^m   Karrer, Urs ⁿ   Genné, Daniel ^o   Nüesch, Reto ^p   Vernazza, Pietro ^q   Bernasconi, Enos ^r   Leduc, Dominic ^s   Satchell, Claudette ^k   Yerly, Sabine ^b   Perrin, Luc ^b   Hill, Andrew ^j   Perneger, Thomas ^b   Phanuphak, Praphan ^a   Furrer, Hansjakob ⁱ   Cooper, David ^a,k   Ruxrungtham, Kiat ^a,l   Hirschel, Bernard ^b   more..

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c Bamrasnaradura Infectious Disease Institute   (Thailand)

^d KHON KAEN UNIVERSITY   (Thailand)

^e MAHIDOL UNIVERSITY   (Thailand)

^f NAVAMINDRADHIRAJ UNIVERSITY   (Thailand)

^g Sanpatong Hospital   (Thailand)

^h Buddhachinnaraj Hospital   (Thailand)

ⁱ UNIVERSITY OF BERN   (Switzerland)

^j UNIVERSITY OF LIVERPOOL   (United Kingdom)

^k UNIVERSITY OF NEW SOUTH WALES   (Australia)

^l CHULALONGKORN UNIVERSITY   (Thailand)

^m LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

ⁿ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^o Hopital de la Chaux de Fonds   (Switzerland)

^p UNIVERSITY HOSPITAL BASEL   (Switzerland)

^q CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^r Ospedale Civico Lugano   (Switzerland)

^s Hôpital d'Annemasse   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; EMTRICITABINE; LAMIVUDINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEMALE; GENITAL CANDIDIASIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; THRUSH; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS LOAD;

EID: 33746479812     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)69153-8     Document Type: Article

References (19)

1. Fellay J., Boubaker K., Ledergerber B., et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 358 (2001) 1322-1327
2. Creese A., Floyd K., Alban A., and Guinness L. Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence. Lancet 359 (2002) 1635-1642
3. Hellinger F., and Fleishman J. Estimating the national cost of treating people with HIV disease: patient, payer, and provider data. J Acquir Immune Defic Syndr 24 (2000) 182-188
4. Walmsley S., and Loutfy M. Can structured treatment interruptions (STIs) be used as a strategy to decrease total drug requirements and toxicity in HIV infection?. J Int Assoc Physicians AIDS Care 1 (2002) 95-103
5. Hogg R., Heath K., Bangsberg D., et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 16 (2002) 1051-1058
6. Taylor S, Allen S, Fidler S, White D, Gibbons S, Fox J et al. Stop study: after discontinuation of efavirenz, plasma concentrations may persist for 2 weeks or longer. San Francisco: 11th Conference on Retroviruses and Opportunistic Infections, 2004.
7. Ananworanich J., Nuesch R., Le Braz M., et al. Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. AIDS 17 (2003) F33-F37
8. Armitage P., and Berry G. Statistical Methods in Medical Research. 2nd edn. (1987), Blackwell Scientific Publications, Oxford
9. Breslow N., and Day N. Statistical methods in cancer research. Volume II. The design and analysis of cohort studies (1987), IARC Scientific Publications no 82, Lyon
10. Fagard C., Bandelier C., Ananworanich J., et al. Biphasic decline of CD4 cell count during scheduled treatment interruptions. AIDS 19 (2005) 439-441
11. Colven R., Harrington R., Spach D., Cohen C., and Hooton T. Retroviral rebound syndrome after cessation of suppressive antiretroviral therapy in three patients with chronic HIV infection. Ann Intern Med 133 (2000) 430-434
12. Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 41 (1992) 1-19
13. Fagard C., Oxenius A., Gunthard H., et al. A prospective trial of strategic treatment interruptions in HIV infection. Arch Intern Medicine 163 (2003) 1220-1226
14. Kinloch-de Loes S., Hoen B., Smith D., et al. Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis 192 (2005) 607-617
15. Molto J., Ruiz L., Romeu J., et al. Influence of prior structured treatment interruptions on the length of time without antiretroviral treatment in chronically HIV-infected subjects. AIDS Res Hum Retroviruses 20 (2004) 1283-1288
16. Ledergerber B., Erard V., Weber R., et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy-The Swiss HIV Cohort Study. JAMA 282 (1999) 2220-2226
17. National Institute of Allergy and Infectious Diseases. A comparison of two ways to manage anti-HIV treatment (the SMART study) (2005). http://www.clinicaltrials.gov/ct/show/NCT00027352?order=2 (accessed February, 2006)
18. Nuesch R., Ananworanich J., Sirivichayakul S., Ubolyam S., Siangphoe U., Hill A., et al. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment. Clin Infect Dis 40 (2005) 728-734
19. National Institute of Allergy and Infectious Diseases. International HIV/AIDS trial finds continuous antiretroviral therapy superior to episodic therapy. Press release (Jan 17, 2006). http://www.nih.gov/news/pr/jan2006/niaid-18.htm (accessed July 18, 2006)